12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Granisol granisetron regulatory update

PediatRx said CMS notified state Medicaid agencies of its decision to reimburse oral Granisol granisetron. The generic serotonin (5-HT3) receptor antagonist is approved in the U.S. to prevent...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >